TY - JOUR
T1 - Mortality after a cerebrovascular event in age-related macular degeneration patients treated with bevacizumab ocular injections
AU - Hanhart, Joel
AU - Comaneshter, Doron S.
AU - Vinker, Shlomo
N1 - Publisher Copyright:
© 2018 Acta Ophthalmologica Scandinavica Foundation. Published by John Wiley & Sons Ltd
PY - 2018/9
Y1 - 2018/9
N2 - Purpose: To analyse the mortality associated with intravitreal injections of bevacizumab for age-related macular degeneration (AMD) in patients previously diagnosed with stroke or transient ischaemic attack (TIA). Methods: We reviewed bevacizumab-treated AMD patients with a diagnosis of stroke or TIA prior to their first bevacizumab injection (n = 948). Those patients, naïve to any anti-vascular endothelial growth factor (anti-VEGF) at the time of stroke/TIA, were then compared to age- and gender-matched patients who had a stroke/TIA at the same time and had never been exposed to anti-VEGF. Survival analysis was performed using adjusted Cox regression. The main outcome measure was survival. Adjusted variables were age, smoking, alcohol abuse, hypertension, diabetes mellitus, obesity, ischaemic heart disease, congestive heart failure and liver cancer. Results: Age and gender distribution of bevacizumab-treated patients and controls were similar (mean age: 83.4 versus 83.7 years, p = 0.3; 51.7% males versus 52.5% males, p = 0.7). The adjusted mortality in patients who received bevacizumab within 3 months after stroke/TIA was significantly different than in patients non-exposed to bevacizumab (OR = 6.92, 95%, CI 1.88–25.43, p < 0.01). Within 6 months after stroke/TIA, the difference in adjusted mortality showed a strong trend (OR = 2.00, 95%, CI 0.96–4.16, p = 0.064). Within 12 months, it was insignificant (OR = 1.30, 95%, CI 0.75–2.26, p = 0.348). Conclusion: We found increased mortality within three months after a cerebrovascular event in patients treated with bevacizumab for AMD compared to patients for whom there was no record of a prescription to any anti-VEGF agent.
AB - Purpose: To analyse the mortality associated with intravitreal injections of bevacizumab for age-related macular degeneration (AMD) in patients previously diagnosed with stroke or transient ischaemic attack (TIA). Methods: We reviewed bevacizumab-treated AMD patients with a diagnosis of stroke or TIA prior to their first bevacizumab injection (n = 948). Those patients, naïve to any anti-vascular endothelial growth factor (anti-VEGF) at the time of stroke/TIA, were then compared to age- and gender-matched patients who had a stroke/TIA at the same time and had never been exposed to anti-VEGF. Survival analysis was performed using adjusted Cox regression. The main outcome measure was survival. Adjusted variables were age, smoking, alcohol abuse, hypertension, diabetes mellitus, obesity, ischaemic heart disease, congestive heart failure and liver cancer. Results: Age and gender distribution of bevacizumab-treated patients and controls were similar (mean age: 83.4 versus 83.7 years, p = 0.3; 51.7% males versus 52.5% males, p = 0.7). The adjusted mortality in patients who received bevacizumab within 3 months after stroke/TIA was significantly different than in patients non-exposed to bevacizumab (OR = 6.92, 95%, CI 1.88–25.43, p < 0.01). Within 6 months after stroke/TIA, the difference in adjusted mortality showed a strong trend (OR = 2.00, 95%, CI 0.96–4.16, p = 0.064). Within 12 months, it was insignificant (OR = 1.30, 95%, CI 0.75–2.26, p = 0.348). Conclusion: We found increased mortality within three months after a cerebrovascular event in patients treated with bevacizumab for AMD compared to patients for whom there was no record of a prescription to any anti-VEGF agent.
KW - anti-VEGF
KW - bevacizumab
KW - mortality
KW - neovascular AMD
KW - stroke
UR - http://www.scopus.com/inward/record.url?scp=85045710383&partnerID=8YFLogxK
U2 - 10.1111/aos.13731
DO - 10.1111/aos.13731
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 29660843
AN - SCOPUS:85045710383
SN - 1755-375X
VL - 96
SP - e732-e739
JO - Acta Ophthalmologica
JF - Acta Ophthalmologica
IS - 6
ER -